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Hematopoietic stem and progenitor cells
(HSPC), attracted by the chemokine
CXCL12, reside in specific niches in the
bone marrow (BM). HSPC migration out of
the BM is a critical process that underlies
modern clinical stem cell transplantation.
Here we demonstrate that enforced HSPC
egress from BM niches depends critically
on the nervous system. UDP-galactose
ceramide galactosyltransferase-deficient
(Cgt/) mice exhibit aberrant nerve con-
duction and display virtually no HSPC
egress from BM following granulocyte col-
ony-stimulating factor (G-CSF) or fucoidan
administration. Adrenergic tone, osteoblast
function, and bone CXCL12 are dysregu-
lated in Cgt/ mice. Pharmacological or
genetic ablation of adrenergic neurotrans-
mission indicates that norepinephrine (NE)
signaling controls G-CSF-induced osteo-
blast suppression, bone CXCL12 down-
regulation, and HSPC mobilization. Further,
administration of a b2 adrenergic agonist
enhances mobilization in both control and
NE-deficient mice. Thus, these results indi-
cate that the sympathetic nervous system
regulates the attraction of stem cells to
their niche.INTRODUCTION
Hematopoietic stem and progenitor cells (HSPCs) reside in
specific niches that control survival, proliferation, self-re-
newal, or differentiation in the bone marrow (BM). Stem cells
closely associate with spindle-shaped N-cadherin- and An-
giopoietin-1-expressing osteoblasts that line the endosteal
bone (Calvi et al., 2003; Zhang et al., 2003; Arai et al.,
2004). In normal individuals, the continuous trafficking of
HSPCs between the BM and blood compartments likely fills
empty or damaged niches and contributes to the mainte-
nance of normal hematopoiesis (Wright et al., 2001; Abko-
witz et al., 2003). Although it has been known for many years
that the egress of HSPCs can be enhanced by multiple ag-
onists, the mechanisms that regulate this critical process
are largely unknown.
The hematopoietic cytokine granulocyte-colony stimulat-
ing factor (G-CSF) is widely used clinically to elicit HSPCmo-
bilization for life-saving BM transplantation and has thus
served as the prototype to gain mechanistic insight about
this phenomenon (Lapidot and Petit, 2002; Papayannopou-
lou, 2004). While mice deficient in the G-CSF receptor (G-
CSFR/) are unresponsive to G-CSF stimulation, G-
CSFR/ HSPCs can be elicited by G-CSF in chimeric
mice that harbored mixtures of G-CSFR+/+ and G-CSFR/
hematopoietic cells, suggesting the contribution of ‘‘trans-
acting’’ signals (Liu et al., 2000). Subsequent studies have
suggested that these trans-acting signals originated from
the release of proteases, including serine- and metallo-pro-
teinases, whose substrates include various molecules impli-
cated in progenitor trafficking such as VCAM-1 (Levesque
et al., 2001), membrane bound Kit ligand (Heissig et al.,
2002), the c-Kit receptor, stromal-derived factor-1 (SDF-1
or CXCL12) (Petit et al., 2002; Levesque et al., 2003), and
its cognate receptor, CXCR4 (Levesque et al., 2003). Among
these, the CXCL12-CXCR4 axis has emerged as a likely ef-
fector because it is the sole chemokine-receptor pair capableCell 124, 407–421, January 27, 2006 ª2006 Elsevier Inc. 407
of attracting HSPCs (Wright et al., 2002), and its disruption
is sufficient to induce mobilization (Broxmeyer et al., 2005).
However, the function of these proteases has been chal-
lenged by other data, indicating that G-CSF-induced mobi-
lization was normal in mice lacking virtually all neutrophil ser-
ine protease activity, even when combined with a broad
metalloproteinase inhibitor (Levesque et al., 2004). This sug-
gests that other proteases and/or other mechanisms are
involved.
We and others have previously shown that the sulfated fu-
cose polymer fucoidan can rapidly elicit HSPC mobilization
(Frenette and Weiss, 2000; Sweeney et al., 2000). We
were intrigued by the similar biological characteristics of fu-
coidan, which is synthesized by certain seaweeds, and sul-
fatide, a sulfated galactolipid synthesized by mammalian
cells (Roberts et al., 1986; Skinner et al., 1991; Waddell
et al., 1995). The synthesis of sulfatide and its nonsulfated
form, galactosylceramide (GalCer), is initiated by the addition
of UDP-galactose to ceramide in a reaction mediated by
UDP-galactose:ceramide galactosyltransferase (Cgt), an en-
zyme highly expressed in oligodendrocytes and Schwann
cells (Sprong et al., 1998). The products of Cgt, collectively
referred to as galactocerebrosides (GCs), are a major com-
ponent of the myelin sheaths that facilitate the transmission
of saltatory conduction (Norton and Cammer, 1984). Pre-
dictably, Cgt/ mice display defects in nerve conduction
and die on postnatal days 18–30 from severe tremor and
ataxia (Bosio et al., 1996; Coetzee et al., 1996).
We initially hypothesized that sulfatide contributed to the
signals mediating HSPC mobilization. During the course of
these studies, we found that Cgt/ mice exhibit defects in
postnatal lymphopoiesis owing to specific deficits in stromal
elements that support the growth and differentiation of lym-
phoid precursors (Katayama and Frenette, 2003). Here, we
report that Cgt/ mice fail to mobilize BM HSPCs following
G-CSF stimulation. Unexpectedly, the deficit is not due to
the absence of BM sulfatide but likely originates from altered
neural influence on osteoblasts. Indeed, we show that sig-
nals emanating from the sympathetic nervous system sup-
press osteoblast function and control the attraction of stem
cells to their niche.
RESULTS
Mobilization Is Severely Impaired in Cgt/ Mice
Cgt littermates were treated with G-CSF to elicit HSPCs from
the BM. Strikingly, there was little mobilization inCgt/mice
compared toCgt+/ or +/+ littermates (Figure 1A). The reduc-
tion of circulatingHSPCs inCgt/micewas not due to lower
numbers of progenitors (Figure 1B) or stem cells (Figure 1C;
see Katayama and Frenette, 2003 for competitive reconstitu-
tion) in the BM. However, the number of common lymphoid
progenitor (CLP) cells (Kondo et al., 1997) was significantly
reduced in Cgt/ mice compared to Cgt+/+ littermates
(Figure 1C), indicating that the previously reported block in
lymphoid differentiation (Katayama and Frenette, 2003) oc-
curs before the CLP stage. To exclude the possibility that
the lymphopenic state contributed to the impaired mobiliza-408 Cell 124, 407–421, January 27, 2006 ª2006 Elsevier Inc.tion in Cgt/ mice, we injected G-CSF in Rag1/ and
IL7Ra/ mice, which have broad deficits in B and T cells.
Circulating CFU-Cs were elicited at levels similar to those of
wild-typemice (data not shown), indicating that the mobiliza-
tion defect in Cgt/ mice is unrelated to lymphopenia.
If fucoidan promoted HSPC mobilization by mimicking
the function of endogenous sulfatide, we would expect
that its administration inCgt/mice might rescue the mobi-
lization defect. To test this possibility, we treated Cgt litter-
mates with fucoidan and assayed for circulating HSPCs.
We found that CFU-Cs were not mobilized by fucoidan in
Cgt/ mice (Figure 1D), suggesting that Cgt expression is
necessary for mobilization triggered by either fucoidan or
G-CSF.
The Mobilization Defect Originates
from the Stromal Compartment
It has been reported that HIV-1 entry into human intestinal
epithelial cell lines can be blocked by either anti-GalCer or
anti-CXCR4 mAbs, suggesting that CXCR4 can cooperate
with GalCer during the fusion process (Delezay et al.,
1997). We assessed the migration of Cgt/ BM mononu-
clear cells toward CXCL12 to investigate whether the mobi-
lization defect arose from CXCR4 dysfunction on Cgt/ he-
matopoietic cells. However,Cgt/ and +/+ cells did not differ
in CXCL12-mediated migration (Figure 1E).
To evaluate further whether the defect in HSPC mobiliza-
tion observed in Cgt/ mice could originate from hemato-
poietic cells, Cgt+/+ or / BM nucleated cells (BMNCs;
CD45.2+) were transplanted into lethally irradiated wild-
type CD45.1 congenic mice. G-CSF-induced mobilization
was similar for highly chimeric (>95% of donor type) Cgt+/+
and / mice (Figure 1F). Thus, these results indicate that
the mobilization defect cannot be transferred through the
transplantation of BM-derived hematopoietic cells.
G-CSF-Induced Bone Marrow Proteolytic Activity
Is Preserved in Cgt/ Mice
Previous studies have revealed that G-CSF induces proteo-
lytic activity in the extracellular BM microenvironment and
that the released proteases, most notably neutrophil elas-
tase, may play an important role in mobilization (Petit et al.,
2002; Levesque et al., 2003). We found that neutrophil elas-
tase activity in supernatants from phorbol-myristate acetate
(PMA)-activated BMNCs was similar for Cgt+/+ and / litter-
mates (Figure 1G), suggesting that Cgt/ BMNCs have
a normal capacity to produce and release this serine prote-
ase. To evaluate more globally the proteolytic environment
in Cgt/ mice, recombinant CXCL12 was incubated with
BM extracellular fluid (BMEF) derived from PBS/BSA or
G-CSF-treated mice, and the degradation of recombinant
CXCL12 was assessed by immunoblotting. A slight deg-
radation of CXCL12 by BMEF was observed in PBS/
BSA-treated mice, but no change was observed for Cgt+/+
and /mice (Figure 1H, lanes 2 and 4), suggesting a normal
production of proteolytic enzymes in theCgt/BMmicroen-
vironment under basal conditions. Consistent with previous
reports (Petit et al., 2002; Levesque et al., 2003), CXCL12
protein was completely degraded after incubation with
BMEF from G-CSF-treated Cgt+/+ mice (Figure 1H, lane 3),
and complete degradation also occurred with BMEF from
G-CSF-treated Cgt/mice (Figure 1H, lane 5). Thus, mobi-
lization is impaired inCgt/mice despite normal proteolysis
in the BM.
CXCL12 Is Expressed in Bone
CXCL12 has been reported to be expressed by endothelial
cells and osteoblasts using immunohistochemical staining
of human BM samples, but the positively stained area was
limited and sporadic (Ponomaryov et al., 2000; Petit et al.,
2002). Knockin mice expressing GFP driven within the
cxcl12 locus exhibited a speckled distribution of fluorescent
stromal cells in the BM (Tokoyoda et al., 2004). We first per-
formed standard immunofluorescence staining of CXCL12 in
frozen sections of wild-type mouse BM but found no specific
staining, likely due to the very low levels of CXCL12 in the BM
(ng range in an entire femur) (Petit et al., 2002; Levesque
et al., 2003). However, staining using the tyramide amplifica-
tion system revealed a specific speckled staining in the BM
parenchyma and, unexpectedly, strong and consistent
staining in bone (Figures 2A–2F). Bone CXCL12 was not re-
stricted to the endosteal region, a putative location of the
stem cell niche (Calvi et al., 2003; Zhang et al., 2003), but
was distributed throughout the entire thickness. To confirm
further the staining specificity, we compared the expression
of CXCL12 between BMEF and protein extracts from bone
by ELISA. Total CXCL12 was in fact higher in bone extracts
than in BMEF (Figure 2G), indicating that bone tissues are
a major reservoir of CXCL12. To assess whether CXCL12
in bone was cell or matrix associated, we stained for
CXCL12 and CD44, an osteocyte marker, but found no ev-
idence of colocalization of the CXCL12 signal with osteo-
cytes (Figures 2H and 2I). However, primary osteoblasts
and the osteoblast precursor cell line ST2 express high levels
of CXCL12 (Ponomaryov et al., 2000 and data not shown),
indicating that CXCL12 is likely deposited in the bone matrix
by osteoblasts but not osteocytes.
Decreased CXCL12 Expression in Bone Correlates
with Mobilization
CXCL12 levels decrease in BMEF during mobilization, and
this effect has been suggested to induce cell egress. There-
fore, we have determined CXCL12 levels by ELISA in the
compact bone as well as in the BMEF of Cgt littermate
mice treatedwith either control PBS/BSAorG-CSF.Wecon-
firmed that CXCL12 was greatly reduced in Cgt+/+ and +/
BMEF after G-CSF injection (Figure 3A). Unexpectedly,
the CXCL12 protein in Cgt/ BMEF was also significantly
reduced by G-CSF (Figure 3A), despite the fact that these
mice do not mobilize HSPCs. While CXCL12 also decreased
in the bone of normal littermate mice following G-CSF ad-
ministration (Figure 3B), there was no reduction of CXCL12
protein levels in the bone of Cgt/mice. These results indi-
cate that CXCL12 levels in bone may correlate better than
that of BM with the release of HSPCs.G-CSF-Induced Transcriptional Downregulation
of CXCL12
While proteases can clearly degrade CXCL12 in vitro, the
maintenance of bone CXCL12 levels in Cgt/mice despite
a robust BM proteolytic activity suggests the contribution of
other regulatory mechanisms. To assess whether CXCL12 is
regulated at the transcriptional level, we evaluated the ex-
pression of the two major isoforms of CXCL12 (a and b) by
quantitative real-time RT-PCR (Q-PCR) in bone and BM tis-
sues of Cgt littermates. The mRNA expression of both
CXCL12 isoforms was profoundly decreased in BM after
G-CSF in both Cgt/ and normal littermates (Figures 3C
and 3D). CXCL12 mRNA levels in bone were moderately de-
creased after G-CSF treatment (p < 0.05 for CXCL12a, p =
0.06 for CXCL12b). Although there was a trend toward de-
creased CXCL12 transcripts in Cgt/ bone after G-CSF,
the difference was not significant, and mRNA levels were still
higher in G-CSF-treated Cgt/ bone than those of steady-
state normal littermates (Figures 3C and 3D). Thus, CXCL12
is transcriptionally regulated in both BM and bone tissues.
Blunted transcriptional downregulation in Cgt/ mice
may contribute to the sustained CXCL12 protein levels in
Cgt/ bone.
Osteoblast Activity Is Altered in Cgt/ Mice
We noted during the staining of osteocytes (Figures 2H and
2I) that bone lining osteoblasts inCgt/mice were generally
flat with little cytoplasmand short projections into bone, while
osteoblasts from littermate controls displayedahomogenous
cobblestone-like appearance sending numerous and deep
projections into the bone matrix (Figures 4A and 4B). The os-
teoblast function was also altered in Cgt/ mice since
plasma osteocalcin levels were significantly reduced as com-
pared with normal littermates (Figure 4C; 39% reduction, n =
6–9, p < 0.001). However, the number of apoptotic osteo-
blasts in Cgt/ mice, as determined by TUNEL assay, was
not increased (data not shown). Further, the absence of
Cgt expression was not directly responsible for the osteo-
blast dysfunction since Cgt mRNA was not detected in vari-
ous osteoblast lineage cells (Figure 4D). To confirm the ab-
sence of Cgt expression in osteoblastic cells, we cultured
MC3T3-E1 and ST2 cell lines with ascorbic acid for 18 days
to induce further maturation. Even under these differentiating
conditions, no Cgt mRNA was detectable (Figures S1A and
S1B). These results thus suggest that osteoblast function is
altered in Cgt/mice through an indirect mechanism.
G-CSF Suppresses Osteoblast Activity
Considering the suppression of osteoblast activity in Cgt/
mice and the fact that osteocalcin levels have been reported
to be reduced after G-CSF administration (Takamatsu et al.,
1998; Froberg et al., 1999), we reasoned that HSPC mobili-
zation by G-CSF may be caused by a rapid downregulation
in osteoblast activity. We evaluated the effect of G-CSF
administration on the expression of Runx2, a transcription
factor controlling osteoblast function and a1(I) collagen,
a major osteoblast gene product and component of the
bone matrix. The expression of both genes was dramaticallyCell 124, 407–421, January 27, 2006 ª2006 Elsevier Inc. 409
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downregulated by G-CSF administration in the bone marrow
of Cgt+/+ mice (Figures 4E and 4F; levels of Runx2; 65% re-
duction, n = 4, p < 0.001, a1(I) collagen; 92% reduction,
n = 4, p < 0.05). However, in Cgt/ mice, the steady-state
levels of Runx2 and a1(I) collagen tended to be lower than
control littermate mice, and the downregulation following
G-CSF administration was not as marked (Figures 4E and
4F). Strikingly, bone-lining osteoblasts in G-CSF-treated
age-matched wild-type C57BL/6 mice resembled those
from steady-state Cgt/ mice (Figure 4G) and exhibited
a flattened appearance with shorter projections into the
bone matrix (Figure 4H). Since osteoblasts do not express
G-CSFR (Figure 4I), these results indicate that G-CSF
suppresses osteoblast activity through an indirect mecha-
nism.
Signals from the Sympathetic Nervous System
Trigger G-CSF-Induced Mobilization
Since Cgt/ mice have severe neurological abnormalities
(Coetzee et al., 1996; Bosio et al., 1996), we explored the
possibility that signals emanating from the nervous system
participate in HSPC mobilization. This possibility would be
consistent with data showing that adrenergic stimulation re-
duces bone formation, indicating that bone formation and
osteoblast function are regulated by the sympathetic ner-
vous system (SNS) (Takeda et al., 2002). To test this hypoth-
esis, we disrupted catecholaminergic neurons by serial peri-
natal injections of 6-hydroxydopamine (6OHDA) (Iversen
et al., 1994). 6OHDA treatment severely reduced the tissue
content of catecholamines (Table S1). We found that the
number of HSPCs mobilized by G-CSF was dramatically re-
duced in 6OHDA-lesioned mice compared to littermates in-
jected with vehicle control (Figure 5A), even though 6OHDA
did not alter baseline CFU-C counts per bone (Figure 5B).
Strikingly, baseline bone-lining osteoblast morphology was
similar between control and 6OHDA-treated mice (Figures
5C and 5E). By contrast, G-CSF suppressed osteoblasts
from control mice but not from 6OHDA-treated littermates
(Figures 5D and 5F).
Neonatal administration of 6OHDA damages both central
and peripheral, dopaminergic and noradrenergic, neurons,
owing to the permeable blood-brain barrier of newborn
mice. To distinguish between the two catecholaminergic
pathways, we studied mice deficient in dopamine b-hydro-xylase (Dbh/), the enzyme necessary for the conversion
of dopamine into norepinephrine (NE) (Thomas et al.,
1995). G-CSF-triggered mobilization of CFU-Cs (Figure 6A)
and the stem cell-enriched fraction (LinSca-1+c-kit+ cells;
Figure 6B) was dramatically compromised in Dbh/ com-
pared to Dbh+/ littermates, indicating that noradrenergic
neurons were required for mobilization by G-CSF. Immuno-
histological analyses of osteoblasts also revealed that mor-
phology correlated with the effectiveness of G-CSF to induce
mobilization, in that osteoblasts from G-CSF-treated Dbh+/
mice exhibited a flattened appearance and shorter projec-
tions, whereas little change was observed in Dbh/ mice
(Figures 6C–6F). In addition, CXCL12 was reduced in bone
protein extracts from Dbh+/mice following G-CSF adminis-
tration, whereas CXCL12 levels were maintained in Dbh/
animals (Figure 6G). Additionally, treatment of C57BL/6
mice for three weeks with a b blocker (propranolol) signifi-
cantly reduced (> 20%) the number of HSPCs elicited by
G-CSF (Figure 6H). To evaluate whether the mobilization
defect in Dbh/ mice could be rescued by the administra-
tion of a b2 adrenergic agonist, we treated a separate cohort
of Dbh+/ and Dbh/ animals with clenbuterol 2 days be-
fore and during G-CSF administration. Clenbuterol rescued
in part the mobilization defect in Dbh/ mice and, interest-
ingly, further enhanced mobilization in Dbh+/ controls (Fig-
ure 6I). By contrast, administration of clenbuterol, by itself, at
the same dose schedule did not trigger mobilization (data not
shown), suggesting that b2 adrenergic signaling is not down-
stream of but rather cooperates with other signals from the
G-CSF receptor.
G-CSF Acts outside the Central Nervous System
Recent studies have revealed that G-CSF can cross the
blood brain barrier and that the G-CSFR is widely expressed
by neurons in the central nervous system (CNS) (Schneider
et al., 2005). That signals from the SNS originating from
the hypothalamus can suppress bone formation also sug-
gests the possibility of a G-CSF target in the CNS (Takeda
et al., 2002). To address this issue, we stereotaxically im-
planted guide cannulae into lateral ventricles of C57BL/6
mice. One week after implantation, mice received G-CSF ei-
ther directly in the CNS by intracerebroventricular (ICV) infu-
sion or systemically by s.c. injection. As shown in Figure 7A,
robust HSPC mobilization occurred only when mice wereFigure 1. Compromised Mobilization in Cgt/ Mice Despite Normal BM Proteolytic Activity
(A) G-CSF-induced mobilization in Cgt littermates. Each circle represents data from an individual mouse, and each bar is the mean.
(B) Frequency of CFU-Cs in steady-state BM from Cgt+/+ and / mice. BFU-E, burst-forming units-erythroid. n = 5.
(C) Numbers of CLPs (Linneg IL-7Rpos Sca-1lo, c-kitlo) and LSK cells (Linneg IL-7Rneg Sca-1pos c-kitpos) in steady-state BM.
(D) Fucoidan-induced mobilization in Cgt littermates. n = 5–19 mice.
(E) CXCL12-mediated migration. BMNCs from Cgt+/+ or /mice were allowed to migrate for 4 hr toward lower chamber containing 100 ng/ml CXCL12a;
n = 6 experiments.
(F) Mobilization phenotype does not result from Cgt/ hematopoietic cells. CD45.1-congenic wild-type mice reconstituted with Cgt+/+ or / BM were
treated with control PBS/BSA or G-CSF, and the number of circulating CFU-Cs was assessed; n = 3–4 mice.
(G) Release of elastase activity from BM mononuclear cells treated with vehicle or PMA (16 nM). Shown are mean ± SEM fold increase in the PMA-treated
group compared to the vehicle-treated group; n = 3–5 mice.
(H) Degradation of rhCXCL12a by BMEF proteases. CXCL12a (50 ng) was incubated with control PBS (lane 1) or BMEF from PBS/BSA-treatedCgt+/+ (lane
2), G-CSF-treated Cgt+/+ (lane 3), PBS/BSA-treated Cgt/ (lane 4), and G-CSF-treated Cgt/mice (lane 5). CXCL12a protein content was assessed by
Western blotting. A representative of two experiments is shown. *p < 0.05; **p < 0.01.Cell 124, 407–421, January 27, 2006 ª2006 Elsevier Inc. 411
Figure 2. Immunofluorescence Staining of CXCL12 in BM and Bone
Wild-type fresh-frozen femoral bone transverse sections were stained with control goat IgG (A and B) or anti-CXCL12 antibody (C and D), followed by se-
quential amplification steps. (A) and (C) are differential interference contrast (DIC) images of (B) and (D) shown to delineate bone and BM tissues. An area of
bone (square) is highlighted in (E) (DIC) and (F) (CXCL12).
(G) CXCL12 protein levels determined by ELISA of BMEF and bone extracts from steady-state wild-type mice; n = 8 mice per group, *p < 0.05.
(H and I) Bone section stained for CD44 (green) to visualize osteocytes and CXCL12 (red). The composite image (I) shows no apparent colocalization of
staining. Black bar, 50 mm; white bar, 20 mm.treated systemically, indicating that the cellular target(s) of
G-CSF lies in the periphery. Since 6OHDA does not penetrate
the CNS of adult mice and causes transient damage of pe-
ripheral noradrenergic neurons (Livnat et al., 1985), we
also evaluated whether G-CSF elicited mobilization in adult
6OHDA-lesioned mice. We found that mobilization was sig-
nificantly reduced in 6OHDA-treated adult mice (Figure 7B),
confirming that a disruption of noradrenergic neurons arising
from peripheral sympathetic ganglia is sufficient to impair the
egress of HSPC.412 Cell 124, 407–421, January 27, 2006 ª2006 Elsevier Inc.NE in peripheral tissues is synthesized and stored in sym-
pathetic nerve endings. In response to sympathetic nerve
impulses, NE is released in the extracellular milieu to interact
with its receptor target(s) and is then degraded or recycled. If
G-CSF augmented NE release or disrupted its reuptake, we
might expect a reduction in NE levels in tissues. To investi-
gate this possibility, we measured NE by HPLC in hearts
and bones of steady-state and G-CSF-treated C57BL/6
mice. While cardiac NE levels in mice that received a single
dose of G-CSF were slightly reduced, we found a dramatic
Figure 3. CXCL12 in BM and Bone during G-CSF-Induced Mobilization
(A and B) CXCL12 protein levels in (A) BMEF and (B) bone were determined by ELISA. Cgt littermates were treated with either PBS/BSA or G-CSF; n = 7–9
mice per group for BMEF and n = 4–5 mice for bone groups.
(C and D) CXCL12mRNA levels in BM and bonewere determined by Q-PCR. Total RNAwas extracted fromBM and bone of control PBS/BSA- and G-CSF-
treated mice. mRNA levels for (C) CXCL12a and (D) CXCL12b were quantified as described in Experimental Procedures. Data are normalized to GAPDH;
n = 4–5 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001.reduction in bone NE levels 3 hr after G-CSF administration,
suggesting that G-CSF may selectively stimulate the activity
of the SNS in bone/BM tissues (Figure 7C). Thus, taken to-
gether, these data suggest that G-CSF-induced adrenergic
signals emerging from the peripheral nervous system regu-
late the egress of stem/progenitor cells from their bone mar-
row niche (Figure 7D).
DISCUSSION
Regulated CXCL12 Expression in Bone
Several studies have suggested that a CXCL12 chemokine
gradient between BM and blood, modifiable by secreted
proteases, plays a key role in HSPC mobilization (Levesque
et al., 2002; Petit et al., 2002). That HSPC mobilization was
virtually absent in Cgt/mice despite robust proteolytic ac-tivity in the BM led us to investigate alternative expression
and regulation of CXCL12. Our studies suggest that
CXCL12 is expressed at high levels in bone tissues and
that bone CXCL12 is dysregulated in Cgt/ mice following
G-CSF administration. CXCL12 staining in bone matrix was
specific, as shown by appropriate antibody controls and by
confirmation with a sandwich ELISA. The fact that fluores-
cence staining in bone was not reported in knockin mice ex-
pressing GFP under the CXCL12 locus is likely due to differ-
ential sorting mechanisms for GFP and CXCL12 (Tokoyoda
et al., 2004). In addition, these results are consistent with
a recent report documenting the presence of CXCL12 in
bone (Sun et al., 2005).
Although osteocytes represent the major cell type present
in bone, they do not appear to synthesize CXCL12. Indeed,
no colocalization between CXCL12 and osteocyte stainingCell 124, 407–421, January 27, 2006 ª2006 Elsevier Inc. 413
Figure 4. Altered Morphology and Function of Osteoblasts of Cgt/ Mice and G-CSF-Stimulated Wild-Type Mice
(A) Projection images of bone-lining osteoblasts of Cgt littermates. Green = CD44, blue = DAPI. Bar: 10 mm.
(B) Average length of osteoblast projections into bone. The length of all projections in one area (30 mm width) were measured using Slidebook software.
n = 12 areas in 4 different sections from 3 different Cgt+/+ and / littermate pairs.
(C) Plasma osteocalcin levels in Cgt+/+ and / littermates were determined by ELISA. n = 6–9.
(D) Cgt mRNA expression assessed by RT-PCR. From lanes 1 to 7: brain, bone, primary osteoblasts, UAMS-33, MC3T3-E1, ST2, MLO-Y4.
(E and F) Quantitative PCR of RNA extracts of BMNCs from control PBS/BSA-treated (open bars) and G-CSF-treated (closed bars) Cgt littermates. (E)
Runx2 and (F) a1(I) collagen were quantified, and data were normalized to GAPDH; n = 4–5.
(G) Projection images of bone-lining osteoblasts from youngwild-typemice treatedwith vehicle PBS/BSAorG-CSF.Green =CD44, blue =DAPI. Bar: 10mm.
(H) Average length of osteoblast projections into bone.
(I) G-CSF receptor mRNA expression assessed by RT-PCR. From lanes 1 to 6: BM, primary osteoblasts, UAMS-33, MC3T3-E1, ST2, MLO-Y4. *p < 0.05,
***p < 0.001.414 Cell 124, 407–421, January 27, 2006 ª2006 Elsevier Inc.
Figure 5. 6OHDA Treatment Reveals a Critical Role for Catecholaminergic Neurons in G-CSF-Mediated Osteoblast Suppression
and HSPC Mobilization
(A) Catecholaminergic lesions were induced early postnatally with 6-hydroxydopamine (6OHDA) or vehicle s.c. injections, and CFU-Cs were elicited by
G-CSF after weaning.
(B) Numbers of CFU-Cs in steady-state BM from 6OHDA- and PBS-treated control mice at weaning age.
(C–F) Projection images of bone-lining osteoblasts from steady-state or G-CSF-mobilized control vehicle or 6OHDA-treated mice.wasobserved in vivo (Figure 2) and, in addition, an osteocyte-
like cell line (MLO-Y4 cells) (Kato et al., 1997) neither ex-
presses CXCL12 mRNA nor secretes CXCL12 protein (Y.K.
and P.S.F., unpublished data). BM CXCL12 has been re-
ported to be expressed by endothelial cells, osteoblasts,
and other stromal elements (Ponomaryov et al., 2000; To-
koyoda et al., 2004). The presence of high concentrationsof CXCL12 in bone and its striking downregulation with G-
CSF-induced osteoblast suppression strongly suggest that
it is primarily deposited by osteoblasts, like many other
growth factors that are enriched in bone matrix (Hauschka
et al., 1988). Indeed, recent studies suggest that BM
CXCL12 is largely produced by osteoblasts (Semerad et al.,
2005). Despite reduced osteoblastic activity, CXCL12 levelsCell 124, 407–421, January 27, 2006 ª2006 Elsevier Inc. 415
Figure 6. G-CSF-Induced Mobilization Requires Adrenergic Signals
(A and B)Dbh+/ and / littermates were injected with G-CSF. Numbers of circulating (A) CFU-Cs and (B) HSC-enriched fraction (LSK cells, Linneg Sca-1pos
c-kitpos) per ml of blood.
(C–F) Projection images of bone-lining osteoblasts from Dbh+/ and / mice at (C–E) baseline and (D–F) after G-CSF.
(G) CXCL12 levels in protein extracts of bones from Dbh+/ and / littermates at baseline and after G-CSF.
(H) G-CSF-induced mobilization in C57BL/6 mice that received a b adrenergic antagonist (propranolol).
(I) Rescue of G-CSF-induced mobilization in Dbh/ mice treated by administration of a b2 adrenergic agonist (clenbuterol). *p < 0.05.are preserved in bone tissues of Cgt/mice (Figure 3), sug-
gesting alternative or compensatory mechanisms by other
stromal elements unconstrained by neural control.
Whereas CXCL12 is constitutively expressed in a variety of
tissues and is necessary for vascular development, intriguing
data have suggested that certain cytokines (e.g., TGF-b and
TNF-a) can decrease CXCL12 transcript levels in stromal
and fibroblastic cell lines via yet unidentified mechanisms
(Fedyk et al., 2001; Wright et al., 2003). TNF-a was a prime
contender to mediate osteoblast suppression because it is
reported to inhibit Runx2, a1(I) collagen, and osteocalcin
(Nanes, 2003) and to be essential for CXCL12 downregula-
tion in the BM during immunization (Ueda et al., 2004). How-
ever, it is unlikely that TNF-a contributes to HSPC mobiliza-
tion since G-CSF administration does not alter TNF-amRNA
levels in the BM and, more importantly, TNF-a-deficient mice
mobilize normal numbers of HSPCs (Y.K. and P.S.F., un-
published data). Whether Runx2, a key transcription factor
that controls the expression of multiple osteoblast genes, in-
fluences the expression of CXCL12 is being tested in the lab-
oratory.
We have found no evidence that soluble GCs are involved
in the survival, growth, or function of osteoblasts since (1)
neither osteoblasts (Figure 4) nor hematopoietic cells (Ka-
tayama and Frenette, 2003) express theCgt gene; (2) neither416 Cell 124, 407–421, January 27, 2006 ª2006 Elsevier Inc.the lymphopoietic nor the HSPC mobilization phenotype are
transplantable (Katayama and Frenette, 2003 and Figure 1F);
(3) GCs are not detectable in BMEF or mouse serum; (4) al-
though Cgt mRNA can be detected by Q-PCR in BM and
bone, GCs are not detectable by high performance thin layer
chromatography, even when alkali-stable lipid extracts from
more than 2 femurs are loaded (Figures S2A–S2C). Thus we
believe that the low expression level of Cgt in these organs
originates from Schwann cells that support the transmission
of neuronal signals.
Neuronal Regulation of the Stem Cell Niche
Neural control of bone metabolism, both trophic and atro-
phic, has been suggested by numerous experimental and
clinical observations. A rich network of nerve fibers was de-
scribed in bone and bone marrow tissues with a significant
subset of fibers reaching stromal cells (Calvo, 1968; Yama-
zaki and Allen, 1990). Immunolabeling studies have revealed
a close association between glutamate-, catecholamine-, or
peptide-containing nerve fibers and osteoblasts or osteo-
clasts in the endosteum (Hohmann et al., 1986; Serre
et al., 1999; Takeda et al., 2002). Blockade of glutamate re-
ceptors was reported to reduce the DNA binding activity and
expression of Runx2 in cultured osteoblasts (Hinoi et al.,
2003). Clinically, peripheral neuropathy in diabetes is an
Figure 7. G-CSF-Induced Mobilization Requires Peripheral Adrenergic Signals and Reduces NE Content in Bone
(A) Mobilization efficiency when G-CSF is administered directly in the central nervous system though ICV infusion. n = 3–4 mice.
(B) G-CSF-induced mobilization in 6OHDA-lesioned adult C57BL/6 mice.
(C) NE content in control or G-CSF-treated (250 mg/kg s.c.) tissues. NE content was determined by HPLC from cardiac and bone (containing BM) tissues.
Heart, n = 4; bones were pooled from the same four mice.
(D) Model for G-CSF-induced HSPC mobilization. G-CSF may activate the outflow of the sympathetic nervous system by influencing directly or indirectly
autonomic neurons in sympathetic ganglions in the periphery. Released NE (1) and a yet unidentified signal (2) mediate osteoblast (OB) suppression, thereby
reducing the synthesis of CXCL12. Posttranslational mechanisms (degradation/inactivation) may also contribute to lowering CXCL12 levels to those per-
missive for HSPC egress from their niche. We propose that OB suppression and CXCL12 reduction lead to HSPCmobilization. In addition, it is possible that
adrenergic neurotransmission also regulates HSPC mobilization through other mechanisms, given the newly identified non-OB stem cell niches (Kiel et al.,
2005).independent risk factor for lower bone mineral density (Rix
et al., 1999). On the other hand, hyperadrenergic activity
and osteopenia are characteristic signs of a human disease
commonly referred to as reflex sympathetic dystrophy. Ther-
apeutic sympathectomy was formerly used to decrease the
discrepancies in limb length in children affected with polio-
myelitis, underscoring the possibility of a dual effect of
bone innervation on bone formation (Ring, 1961). The effect
of the sympathetic nervous system on bone formation has
only recently been elucidated using genetic models (Chien
and Karsenty, 2005). These studies revealed that leptin in-
duced bone loss through SNS-derived signals originating
in the ventromedial hypothalamic nuclei (Takeda et al.,
2002). The atrophic appearance of osteoblasts in both G-
CSF-treated wild-type mice and steady-state Cgt/ mice
and the fact that osteoblasts do not express G-CSFR or
Cgt genes strongly supported the possibility that the rapid
G-CSF-mediated osteoblast suppression is controlled by
the nervous system.Several lines of evidence indeed indicate that sympathetic
signals contribute to the dramatic reduction in osteoblast
function that follows G-CSF administration. First, the admin-
istration of 6OHDA in neonatal or adult mice inhibited mobi-
lization without toxicity to the HSPC content in the BM. Sec-
ond, G-CSF-induced HSPC mobilization was severely
altered in NE-deficient mice. Third, osteoblast function was
suppressed by G-CSF in control mice but not in mice with
impaired SNS activity. Fourth, mobilization efficiency corre-
lated with bone CXCL12 levels that were suppressed in
Dbh+/ and preserved in Dbh/mice. Fifth, the administra-
tion of a b2 adrenergic agonist rescued the mobilization de-
fect in Dbh/ mice and enhanced mobilization in control
mice. Finally, administration of a b adrenergic antagonist sig-
nificantly reducedmobilization. The lower inhibition observed
with b blockers compared with neonate 6OHDA-treated or
Dbh/mice may result from incomplete inhibition of norad-
renergic signaling. Consistent with this possibility, pharma-
cologic inhibition of b adrenergic receptors did not affectCell 124, 407–421, January 27, 2006 ª2006 Elsevier Inc. 417
bone resorption to the extent observed for genetic ablation
of the b2 adrenergic receptor (Elefteriou et al., 2005).
While we found a strong correlation between osteoblast
suppression and HSPC mobilization, our studies do not
prove a causal relationship. It is interesting that another
stem cell niche was recently identified near endothelial cells
(Kiel et al., 2005). While it is temping to speculate that sym-
pathetic innervation, which accompanies the BM vascula-
ture, may regulate the endothelial stem cell niche, whether
osteoblasts can influence the attraction of these stem cells
in the BM is unknown.
The involvement of the SNS in HSPC mobilization sug-
gested that the target of G-CSF may be extramedullary
and may in fact be neuronal or glial. On the other hand, G-
CSFR expression on a transplantable hematopoietic cell
was shown to be required for G-CSF-induced mobilization
(Liu et al., 2000). Based on studies describing leptin-medi-
ated neuronal control of osteoblast function (Takeda et al.,
2002; Elefteriou et al., 2005) and the fact that leptin and
G-CSF receptors display a high degree of homology (Tarta-
glia et al., 1995), we have considered the possibility that
G-CSF signals directly in the hypothalamus through the lep-
tin receptor. However, expression of the leptin receptor does
not appear to be required for HSPCmobilization since it pro-
ceeds normally in leptin receptor-deficient db/db mice (Fig-
ure S3). In addition, the impaired mobilization after ICV infu-
sion of G-CSF or in mice that have a peripheral SNS defect
(6OHDA-lesioned adult mice) indicates that the cellular tar-
get for G-CSF is in the periphery.
Our results suggest that G-CSFmay increase sympathetic
tone in bone and that both G-CSF and adrenergic signaling
cooperate to trigger HSPC egress (Figure 7D). Supporting
evidence for a cooperation between these signals comes
from the fact that clenbuterol does not by itself induce mobi-
lization but that it can rescue at least in part the defect in
Dbh/ mice and enhance the mobilizing effects of G-CSF
in Dbh+/ mice. Whether G-CSF can modulate the release/
reuptake of NE by acting directly on neurons of sympathetic
ganglia or via neighboring glial cells is currently unknown.
Trophic Neuronal Signals to Osteoblast
The constitutive suppression of osteoblast function inCgt/
mice might be due to increased sympathetic tone (Takeda
et al., 2002) or, alternatively, a reduction in putative neurally
transmitted trophic signals. Osteoblasts have been reported
to express receptors for several neuropeptides, suggesting
that they could indeed integrate multiple neuronal signals
(Togari, 2002).We havemeasured NE turnover in cardiac tis-
sues of Cgt littermates and found a longer halflife in Cgt/
hearts, indicating reduced peripheral sympathetic activity
in the null mice (Figure S4). Although this finding would be
consistent with their mobilization defect, b2 adrenergic stim-
ulation did not rescue the mobilization defect of Cgt/ ani-
mals (data not shown). It is possible that the phenotype of
Cgt/mice may result from their basal osteoblast suppres-
sion. The difference in osteoblast morphology at baseline
between Cgt/ mice and mice harboring compromised
SNS signaling clearly suggests deficits in Cgt/ mice that418 Cell 124, 407–421, January 27, 2006 ª2006 Elsevier Inc.lie outside noradrenergic innervation (compare Figure 4A
with Figures 5E and 6E) and imply the presence of physiolog-
ical neurally transmitted trophic signals to osteoblasts.
A Common Niche for Stem Cells and Common
Lymphoid Progenitor Cells?
We have previously reported a lymphopoietic defect in
Cgt/mice that was associated with a deficit in the stromal
microenvironment supporting lymphoid commitment (Ka-
tayama and Frenette, 2003). The steady-state reductions
in CLP content in the BMofCgt/mice and the reduced os-
teoblast activity reported herein suggest that osteoblasts
may support the commitment of stem cells toward the lym-
phoid lineage. Consistent with this possibility, postnatal ab-
lation of osteoblasts was recently shown to reduce bone
marrow B cell content by 97%, while HSPC numbers
were much less affected (Visnjic et al., 2004), indicating
that the earliest committed lymphoid progenitor cell may re-
quire osteoblasts for survival, proliferation, or differentiation.
A close relationship between CLP and the stem cell niche is
further suggested by the expression of the Notch-1 ligand,
Jagged-1, in the osteoblastic niche and the fact that
Notch-1 can promote both stem cell self-renewal and differ-
entiation toward the lymphoid lineage (Calvi et al., 2003; Pui
et al., 1999; Radtke et al., 1999). More differentiated B cell
precursors (B220+flk2+), distant from the endosteum, are
closely associated with CXCL12-expressing stromal cells,
which do not express the Notch-1 ligands Jagged-1 or
Delta-like-1 (Tokoyoda et al., 2004). Further studies are
thus needed to determine whether the nervous system influ-
ences homeostatic migration of stem cells among cellular
niches in the BM.
In summary, we show here that the sympathetic nervous
system regulates the egress of stem and progenitor cells
from their niche. These results raise the interesting possibility
that alterations in the sympathetic tone may explain the con-
spicuous variability in mobilization efficiencies among normal
donors (Korbling et al., 1995). Modulation of the sympathetic
outflow to the stem cell niche represents a novel strategy to
increase the efficiency of HSPC harvests for stem cell-based
therapeutics.
EXPERIMENTAL PROCEDURES
Animals
Cgt+/+, +/, and / littermate mice, backcrossed seven generations into
the C57BL/6 background, were used for experiments performed be-
tween 3 and 4 weeks of age. Genotype was determined at weaning by
PCR as described (Coetzee et al., 1996). C57BL/6-CD45.1 congenic
mice were purchased from Charles River Laboratories (Frederick Cancer
Research Center, Frederick, MD). Dbh littermate mice were bred and res-
cued with L-threo-3,4-dihydroxyphenylserine (L-DOPS, Sumitomo Phar-
maceuticals, Osaka, Japan) as described in Supplemental Experimental
Procedures. Mice were housed at Mount Sinai School of Medicine, where
experimental procedures were approved by the IACUC.
Mobilization of Hematopoietic Progenitors
To induce HSPC mobilization, mice were injected with recombinant hu-
man G-CSF (Filgrastim, Amgen, Thousand Oaks, CA, 250 mg/kg/day,
every 12 hr, 8 divided doses, s.c.) in PBS supplemented with 0.1%
endotoxin-free bovine serum albumin (BSA) or fucoidan (Sigma; 2 doses
of 100 mg/kg with 2 hr interval, i.p.) in PBS. Blood was harvested 3 hr
(G-CSF) or 1 hr (fucoidan). CFU-C assays were carried out as previously
described (Katayama et al., 2003).
Intracerebroventricular G-CSF Infusion
A chronic guide cannula (1.0 mm) was implanted stereotaxically into the
lateral ventricle (coordinates AP, 0.7 mm; DV, 2.4 mm; ML, 1.5 mm,
from bregma). One week after implantation, mice received a reduced
dose of G-CSF (25 mg/kg daily for 4 doses) either by ICV infusion (rate:
0.4 ml/min) or by s.c. injection.
Pharmacological Disruption or Induction of SNS-Signals
Newborn C57BL/6 mice were injected s.c. with 6OHDA (100 mg/kg,
Sigma) or vehicle (saline) on postnatal days 2, 4, 6, 8, and 9. HSPC mo-
bilization was induced at 3 weeks of age. For SNS disruption in adult
C57BL/6 mice, 4-week-old animals were injected i.p. with 2 doses of
6OHDA or vehicle, 100 mg/kg on day 0, 250 mg/kg on day 2, and G-
CSF treatment was begun on day 5. For b adrenergic receptor blockade,
4-week-old C57BL/6 mice were treated with propranolol (0.5 g/l in drink-
ing water, Sigma) or control pure water for 3 weeks prior to mobilization.
For rescue experiments, clenbuterol (2 mg/kg/day, i.p.) was injected
starting day 2 prior to and continued during G-CSF treatment.
Generation of Chimeric Mice
Chimeric mice were generated by injection of 1  106 Cgt+/+ or /mice
(CD45.2) BMNCs into lethally irradiated (12 Gy, split dose) C57BL/6-
CD45.1 congenic mice (Frenette and Weiss, 2000).
Migration Assay and Enzymatic Release
Transwell migration and elastase release assays were performed as de-
scribed (Hidalgo et al., 2004).
ELISA
CXCL12 ELISA was done exactly as described (Petit et al., 2002). Mouse
plasma osteocalcin was measured using ELISA kit (Biomedical Technol-
ogies Inc., Stoughton, MA) according to manufacturer’s recommenda-
tion.
Flow Cytometry and Immunofluorescence Microscopy
Detailed methods for flow cytometry and immunofluorescence analyses
of bone sections are available in Supplemental Experimental Procedures.
Bone Protein Extraction, Catecholamine Measurements,
and Western Blot Analyses
Protein extraction from bone, biogenic amine determination, BM, and
CXCL12 immunoblotting were carried out as detailed in Supplemental
Experimental Procedures.
RNA Extraction and Q-PCR
Methods, primers, and PCR conditions are available in Supplemental Ex-
perimental Procedures and Table S3.
Statistical Analysis
All values are reported as mean ± SEM. Statistical significance for two un-
paired groups was assessed by the Student’s t test or Mann-Whitney U
test. Significance was set at p < 0.05.
Supplemental Data
Supplemental Data include four figures, three tables, Experimental Proce-
dures, and References and can be found with this article online at http://
www.cell.com/cgi/content/full/124/2/407/DC1/.
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